+ Watch ACUR
on My Watchlist
A pharmaceutical company engaged in research, development and manufacture of innovative Aversion(r) Technology and related product candidates.
My first Acura green thumb didn't work out so well due to a combination of poor timing on my part with poor tracking of the ticker by CAPS. Nevertheless, I'll make another bet that this company isn't quite ready to give up the ghost. The story of the stock has been a gradual decline which will eventually arrive at zero, with intermittent short-lived spikes due to disproportionate buying by naive retail investors on purported positive news. Another PR of pathetic revenues for doomed products Oxecta and Nexafed hasn't done wonders for the share price. It's easy to get burned playing stocks like this but the fun of riding the spike more than makes up for the pain of the decline.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions